Publicacions - IR Sant Pau

Cercar

01/06/2025 Exploring gender disparities in neurology education: Insights from Spanish medical schools

Lambea-Gil, A, Gil-Navarro, S, Jim nez, M, Mart nez-S nchez, P, Mir, P, Oreja-Guevara, C, Pascual-Gomez, J, P rez-Sempere, A, Santos-Lasaosa, S, Frank-Garc a, A, D ez-Tejedor, E. Exploring gender disparities in neurology education: Insights from Spanish medical schools. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 End-of-life and palliative sedation in the neurology inpatient unit of a tertiary hospital

Morales-Gonz lez, C, Lambea-Gil, A, Barroeta-Espar, I, Olmedo-Saura, G, Prats-S nchez, L, Ramos-Pachon, A, Ros-Castello, V, Vesperina-Castro, A, Mart nez-Dome o, A. End-of-life and palliative sedation in the neurology inpatient unit of a tertiary hospital. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Neurophobia and the perception of neurology among neurologists in Spain

Saldana-Inda, I, Lambea-Gil, A. Neurophobia and the perception of neurology among neurologists in Spain. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Exploring the Association of Cerebral Vasoreactivity in Patients with Acute Intracerebral Hemorrhage with Functional Outcomes

García, JM, Gil, AL, Pachón, AR, Díaz, GE, Jiménez, MG, Renom, PC, Gómez, MI, Frisk, LK, Vega, CF, Zanoletti, M, Simón, AA, Fabrega, CG, Grifol, NP, Chorro, IM, Sánchez, LP, Vidal, JMF, Fernandez, JJS, Fabregas, JM, Durduran, T. Exploring the Association of Cerebral Vasoreactivity in Patients with Acute Intracerebral Hemorrhage with Functional Outcomes. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2025; 45(1)DOI:. PMID:. IF:4.500(Q1/2D).

01/01/2022 Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement

Osuna, AG, Rojas, LF, Lamas, C, Roig, XA, Pla-Junca, F, Videla, S, Martinez-Zapata, MJ, Valle, M, Font A., Fernández J.A., Rodriguez Prieto, M, Banos, V. Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. CLINICAL PHARMACOKINETICS. 2022; 61(1)DOI:10.1007/s40262-021-01043-9. PMID:34255299. IF:4.500(Q2/3D).

01/12/2021 Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study

Siddiqi, ZA, Nowak, RJ, Mozaffar, T, O'Brien, F, Yountz, M, Patti, F, Illa I., Cortés-Vicente E., Díaz-Manera J., Querol L.A., Rojas-García R., Vidal-Fernandez N., Nye, Joan L.. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. MUSCLE & NERVE. 2021; 64(6)DOI:10.1002/mus.27422. PMID:34590717. IF:3.852(Q2/5D).

01/10/2021 Intravenous immunoglobulin treatment for mild Guillain-Barre syndrome: an international observational study

Verboon, C, Harbo, T, Cornblath, DR, Hughes, RAC, van Doorn, PA, Lunn, MP, Gorson, KC, Barroso, F, Kuwabara, S, Galassi, G, Lehmann, HC, Kusunoki, S, Reisin, RC, Binda, D, Cavaletti, G, Jacobs, BC, Querol L.A., Wirtz, Paul Willem. Intravenous immunoglobulin treatment for mild Guillain-Barre syndrome: an international observational study. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2021; 92(10)DOI:10.1136/jnnp-2020-325815. PMID:34103340. IF:13.654(Q1/1D).

01/11/2023 Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis.

Esteller D, Morrow J, Alonso-Pérez J, Reyes D, Carbayo A, Bisogni G, Cateruccia M, Monforte M, Tasca G, Alangary A, Marini-Bettolo C, Sabatelli M, Laura M, Ramdharry G, Bolaño-Díaz C, Turon-Sans J, Töpf A, Guglieri M, Rossor AM, Olive M, Bertini E, Straub V, Reilly MM, Rojas-García R, Díaz-Manera J. Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis.. NEUROMUSCULAR DISORDERS. 2023; 33(10)DOI:10.1016/j.nmd.2023.08.010. PMID:37704504. IF:2.700(Q2/4D).

01/10/2023 Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy.

Schiava M, Ikenaga C, Topf A, Caballero-Ávila M, Chou TF, Li S, Wang F, Daw J, Stojkovic T, Villar-Quiles R, Nishino I, Inoue M, Nishimori Y, Saito Y, Katsuno M, Noda S, Ito C, Otsuka M, Nahir S, Manousakis G, Walk D, Quinn C, Alfano L, Sahenk Z, Tasca G, Monforte M, Sabatelli M, Bisogni G, Oldfors A, Rydeliu A, Pal E, Paradas C, Velez B, De Bleecker JL, Farugia ME, Longman C, Harms MB, Ralston S, Zanoteli E, Macedo Serafim da Silva A, Sotoca J, Juntas-Morales R, Bevilacqua J, Balart M, Talbot S, Straub V, Guglieri M, Marini-Bettolo C, Diaz-Manera J, Weihl CC. Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy.. Neurology-Genetics. 2023; 9(5)DOI:10.1212/NXG.0000000000200093. PMID:37588275. IF:(Q/D).

01/08/2023 Cumulative Genetic Score and C9orf72 Repeat Status Independently Contribute to Amyotrophic Lateral Sclerosis Risk in 2 Case-Control Studies.

Dou J, Bakulski K, Guo K, Hur J, Zhao L, Saez-Atienzar S, Stark A, Chia R, García-Redondo A, Rojas-Garcia R, Vázquez Costa JF, Fernandez Santiago R, Bandres-Ciga S, Gómez-Garre P, Periñán MT, Mir P, Pérez-Tur J, Cardona F, Menendez-Gonzalez M, Riancho J, Borrego-Hernández D, Galán-Dávila L, Infante Ceberio J, Pastor P, Paradas C, Dols-Icardo O, Traynor BJ, Feldman EL, Goutman SA. Cumulative Genetic Score and C9orf72 Repeat Status Independently Contribute to Amyotrophic Lateral Sclerosis Risk in 2 Case-Control Studies.. Neurology-Genetics. 2023; 9(4)DOI:10.1212/NXG.0000000000200079. PMID:37293291. IF:(Q/D).

01/01/2023 Is pronator quadratus muscle repair required after anterior plate fixation for distal radial fractures? A prospective randomized comparative study.

Lamas C, Arenas J, Almenara M, Rojas R, Fa-Binefa M, Toro-Aguilera A. Is pronator quadratus muscle repair required after anterior plate fixation for distal radial fractures? A prospective randomized comparative study.. The Journal Of Hand Surgery, European Volume. 2023; DOI:10.1177/17531934231192337. PMID:37684023. IF:(Q/D).

01/12/2025 Neural synaptic vesicle autoimmunity following aerosolized porcine neural tissue exposure: insights into autoimmune inflammatory polyradiculoneuropathy

Hinson, SR, Gupta, P, Paramasivan, NK, Dyck, PJB, Lennon, VA, Lachance, DH, Knight, AM, Rezk, M, Karsten, C, LaFrance-Corey, RG, Staff, NP, Hrstka, SC, Wu, JC, Klein, CJ, Zekeridou, A, Mckeon, A, Pittock, SJ, Lleixà, C, Querol, L, Dasari, S, Mills, JR, Dubey, D. Neural synaptic vesicle autoimmunity following aerosolized porcine neural tissue exposure: insights into autoimmune inflammatory polyradiculoneuropathy. EBioMedicine. 2025; 122DOI:10.1016/j.ebiom.2025.106053. PMID:41337934. IF:10.800(Q1/1D).

01/12/2025 Peripheral Nerve Society Training Grant Program: An Exciting Opportunity Not to Be Missed

Alberti, P, Querol, L. Peripheral Nerve Society Training Grant Program: An Exciting Opportunity Not to Be Missed. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(4)DOI:10.1111/jns.70076. PMID:41236205. IF:3.200(Q2/4D).

01/12/2025 Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Allen, JA, Lehmann, HC, Nobile-Orazio, E, Querol, L, Rajabally, YA. Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(4)DOI:10.1111/jns.70067. PMID:41054275. IF:3.200(Q2/4D).

01/10/2025 ADHERE plus trial interim analysis: long-term safety and efficacy of efgartigimod in chronic inflammatory demyelinating polyneuropathy (CIDP)

Eggers, C, Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Lauria, G, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, van Doorn, P, Lewis, R. ADHERE plus trial interim analysis: long-term safety and efficacy of efgartigimod in chronic inflammatory demyelinating polyneuropathy (CIDP). NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105858. PMID:. IF:2.800(Q2/5D).

01/10/2025 208-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers

Toscano, A, Bratkovic, D, Claeys, K, Díaz-Manera, J, Mozaffar, T, Roberts, M, Schoser, B, van der Ploeg, A, Jain, V, Holdbrook, F, Moore, P, O'Brien-Prince, K, Kishnani, P. 208-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105857. PMID:. IF:2.800(Q2/5D).

01/10/2025 Brachio-cervical inflammatory myopathy: evidence for a distinct form of inflammatory muscle disease

Kleefeld, F, Vigo, EG, Gamboa, JT, Funke, A, Roos, A, Mensch, A, Gehrig, J, Ruck, T, Mossakowski, A, Llanso, L, Bortolani, S, Torchia, E, Casal-Dominguez, M, Pinal-Fernandez, I, Mammen, A, Tasca, G, Preusse, C, Stenzel, W. Brachio-cervical inflammatory myopathy: evidence for a distinct form of inflammatory muscle disease. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105458. PMID:. IF:2.800(Q2/5D).

01/09/2025 Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks

Moreno, AA, Presas-Rodríguez, S, Gonzalez-Garcia, AM, Teniente-Sera, A, Martínez-Cáceres, EM, Querol, L, Martín-Aguilar, L, Meca-Lallana, JE, Dos Santos, CE, Millán, J, López, GV, Orgaz, ATC, Ruiz, VC, Anunciación, BAJ, Hervas, JV, Ruiz, LB, Bravo, GCA, Ramo, C. Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).

01/09/2025 Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies

Luce, L, Kocak, G, Alonso-Pérez, J, Straub,, Töpf, A, Díaz-Manera, J. Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies. NEUROMUSCULAR DISORDERS. 2025; 53DOI:. PMID:. IF:2.800(Q2/5D).

01/09/2025 Denervated human muscle fibers promote reinnervation via neurotrophic factor release in SMA and ALS

Gokul-Nath, R, Collins, C, Valverde, L, Lleixa, C, Verdu-Diaz, J, Di Lorenzo, A, Llarch, P, Querol, L, Marini-Bettolo, C, Rojas-Garcia, R, Diaz-Manera, J. Denervated human muscle fibers promote reinnervation via neurotrophic factor release in SMA and ALS. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105462. PMID:. IF:2.800(Q2/5D).

01/09/2025 Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT

Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).

03/03/2025 Enhancing Lateral Resolution Using Two-Colour Direct Stochastic Optical Reconstruction Microscopy to Unravel Synaptic Tau Pathology in Alzheimer's Disease

Sánchez-Aced, E, Moya-Llamas, B, Escabias, JA, Torres, S, Colom-Cadena, M, Pegueroles, J, de Quintana-Schmidt, C, Bayes, A, Molina-Porcel, L, Aldecoa, I, Belbin, O, Fortea, J, Spires-Jones, T, Pujals, S, Sirisi, S, Lleo, A. Enhancing Lateral Resolution Using Two-Colour Direct Stochastic Optical Reconstruction Microscopy to Unravel Synaptic Tau Pathology in Alzheimer's Disease. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2025; 51(2)DOI:10.1111/nan.70010. PMID:40025904. IF:3.400(Q1/3D).

11/02/2025 Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic"

Martín-Aguilar, L, Querol, L. Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic". EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(2)DOI:10.1111/ene.70069. PMID:39931912. IF:3.900(Q1/3D).

03/02/2025 Rapid Quantitative Assessment of Muscle Sodium Dynamics After Exercise Using 23Na-MRI in Dysferlinopathy and Healthy Controls

Neal, MA, Bolano-Diaz, CF, Richardson, M, Michell-Sodhi, J, Muni-Lofra, R, James, MK, Hollingsworth, KG, Hilsden, H, Wilson, I, Blamire, AM, Straub, V, Thelwall, PE, Diaz-Manera, J. Rapid Quantitative Assessment of Muscle Sodium Dynamics After Exercise Using 23Na-MRI in Dysferlinopathy and Healthy Controls. Journal of Cachexia Sarcopenia and Muscle. 2025; 16(1)DOI:10.1002/jcsm.13709. PMID:39900102. IF:9.100(Q1/1D).

01/03/2026 Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease

Dominguez-González, C, Iannucci, D, Clark, J, Martin-Jiménez, P, Hold, S, Oliva, P, Bischinger, A, Gallardo, E, Diaz-Manera, J. Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease. NEUROMUSCULAR DISORDERS. 2026; 60DOI:10.1016/j.nmd.2026.106359. PMID:41638029. IF:2.800(Q2/5D).

01/02/2026 Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic

Vesperinas, A, Rocaspana-Codana, J, Reyes-Leiva, D, Caballero-Avila, M, Carbayo, A, Collet-Vidiella, R, Llanso, L, Gallardo, E, Turon-Sans, J, Rojas-Garcia, R, Cortes-Vicente, E. Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic. NEUROMUSCULAR DISORDERS. 2026; 59DOI:10.1016/j.nmd.2025.106284. PMID:41442860. IF:2.800(Q2/5D).

01/01/2026 E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders

Schirinzi, E, Bochicchio, MA, Lochmüller, H, Vissing, J, Jordie-Diaz-Manerae, Evangelista, T, Plançon, JP, Fanucci, L, Marini, M, Tonacci, A, Mancuso, M, Segovia-Kueny, S, Toscano, A, Angelini, C, Schoser, B, Sacconi, S, Siciliano, G, e-NMD Grp. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders. Journal Of Neuromuscular Diseases. 2026; 13(1)DOI:10.3233/JND-230091. PMID:38728200. IF:3.400(Q2/3D).

01/01/2026 Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial

Allen, JA, Querol, L, Suresh, N, Remmerie, A, Mole, T, McCoy, K, Butler, L, van Hoorick, B, Kuwabara, S, van Doorn, PA, Lewis, RA. Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial. Therapeutic Advances in Neurological Disorders. 2026; 19DOI:10.1177/17562864251405202. PMID:41583073. IF:4.100(Q1/2D).

01/12/2025 ORGANIZATIONAL SUPPORT IN ADOPTING NEW TREATMENTS FOR GENERALIZED MYASTHENIA GRAVIS

Armangué, T, Gómez-Ballesteros, R, Querol, L, Gutiérrez-Gutiérrez, G, Sotoca, J, Luque, AA, Villaverde, R, Reyes, V, Salas, E, Diaz, P, Maurino, J, Cortés-Vicente, E. ORGANIZATIONAL SUPPORT IN ADOPTING NEW TREATMENTS FOR GENERALIZED MYASTHENIA GRAVIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

01/09/2025 HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL

Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

01/08/2025 Absence of Anti-LGI4 Autoantibodies in a European Cohort of CIPD Patients

Cegarra, PL, Caballero-Avila, M, De Lorenzo, A, Lleixà, C, Collet-Vidiella, R, Martín-Aguilar, L, Pascual-Goñi, E, Querol, L. Absence of Anti-LGI4 Autoantibodies in a European Cohort of CIPD Patients. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 CIDP With Anti-GM1 IgM Antibodies: A Continuum With Multifocal Motor Neuropathy

Collet-Vidiella, R, Caballero-Avila, M, Llarch, P, Tejada-Illa, C, Pascual-Goñi, E, Martín-Aguilar, L, Lleixà, C, Vesperinas, A, Carbayo-Viejo, A, Llansó, L, Rojas, R, Querol, L. CIDP With Anti-GM1 IgM Antibodies: A Continuum With Multifocal Motor Neuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Balance Assessment in Patients With Peripheral Neuropathies Using Digital Biomechanical Biomarkers

Illa, CT, Pegueroles, J, Claramunt-Molet, M, Pi-Cervera, A, Heras-Delgado, A, Gascón-Fontal, J, Idelsohn-Zielonka, S, Rico, M, Vidal, N, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Collet-Vidiella, R, Llarch, P, Llansó, L, Carbayo-Viejo, A, Vesperinas, A, Querol, L, Pascual-Goñi, E. Balance Assessment in Patients With Peripheral Neuropathies Using Digital Biomechanical Biomarkers. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Exploratory Biomarker Analyses in a Phase 2 Trial of Riliprubart for Chronic Inflammatory Demyelinating Polyneuropathy

Querol, L, Hourcade, S, Chow, T, Chen, Y, Levit, M, Hammond, TR, Kramer, ML, Ternes, N, Seluzhytsky, A, Alonso-Alonso, M, Atassi, N, Lewis, RA. Exploratory Biomarker Analyses in a Phase 2 Trial of Riliprubart for Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 ADHERE plus Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy

Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, Van Doorn, PA, Lewis, RA. ADHERE plus Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Safety and Efficacy of Riliprubart in CIDP: 76-Week Phase 2 Trial Results

Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and Efficacy of Riliprubart in CIDP: 76-Week Phase 2 Trial Results. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study

Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Allen, J, Nobile-Orazio, E, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study

Hewamadduma, C, Peric, S, Claeys, K, Querol, L, Altamimi, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Szmyd, G, Vujcic, M, Cadour, S, Van de Steen, O, Arvin-Berod, C, Allen, J. Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Riliprubart Phase 3 MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally

Falzone, Y, Sommer, C, Querol, L, Allen, J, Merkies, I, Van Doorn, P, Wallstroem, E, Lu, Y, Alonso-Alonso, M, Atassi, N, Lewis, RA. Riliprubart Phase 3 MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive/Relapsing Active Disease: ADHERE Analysis

Stettner, M, Allen, J, Rinaldi, S, Pinter, GL, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Skripuletz, T, Lewis, R, Van Doorn, PA. Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive/Relapsing Active Disease: ADHERE Analysis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Comparative Effectiveness In IGOS: ANX005 Versus Intravenous Immunoglobulin or Plasma Exchange For Guillain-Barre Syndrome

Wiegers, E, Steyerberg, E, Rajpar, A, Paliwal, P, Kanani, K, Kroon, HA, Dananberg, J, Cornblath, D, Willison, H, Kim, M, Gorson, K, Querol, L, Hartung, HP, Islam, Z, van Doorn, PA, Jacobs, B. Comparative Effectiveness In IGOS: ANX005 Versus Intravenous Immunoglobulin or Plasma Exchange For Guillain-Barre Syndrome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Development and Validation of a Digital Tool to Simplify Use of Guidelines For CIDP Diagnosis

Dymm, B, Van den Bergh, P, London, Z, Lewis, R, Querol, L, Harbo, T, Allen, J, Hadden, R, Van Doorn, PA. Development and Validation of a Digital Tool to Simplify Use of Guidelines For CIDP Diagnosis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Serum Neurofilament Light Chain in The International GBS Outcome Study: Predicting Disease Course and Outcome

Rajpar, A, Wiegers, E, Thomma, R, van Tilburg, S, Plomp, L, Sammelius, L, van Rijs, W, Harbo, T, Hartung, HP, Islam, Z, Lunn, M, Querol, L, Huizinga, R, Jacobs, B. Serum Neurofilament Light Chain in The International GBS Outcome Study: Predicting Disease Course and Outcome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION

Querol, L, Peric, S, Cadour, S, Rigby, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Mashchenko, O, Van Hoomissen, I, Allen, J, Katzberg, H, Kuwabara, S, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Management of Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists

Querol, L, Lewis, R, Sommer, C, Bromberg, M, Barrera-Sierra, S, Arvin-Berod, C, Nisbet, P, Gelinas, D, Guptill, J, Wood, J. Management of Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Empasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA Study

van der Pol, WL, Krijgsman, D, Querol, L, Persson, E, Rutjens, S, Cadour, S, Dijkxhoorn, K, Bloemenkamp, LM, de Zeeuw, E, Vujcic, M, Van de Walle, I. Empasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Test Database and International Collaboration For Improving Peripheral Neurology in Resource Limited Settings

Eric, CT, Querol, L, Rodés, M, Thirugnanam, UN. Test Database and International Collaboration For Improving Peripheral Neurology in Resource Limited Settings. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Impact of Prior Chronic Inflammatory Demyelinating Polyneuropathy Treatments in the ADHERE Trial: Post Hoc Analyses

Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, van Doorn, P, Lewis, R. Impact of Prior Chronic Inflammatory Demyelinating Polyneuropathy Treatments in the ADHERE Trial: Post Hoc Analyses. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/08/2025 Genetic Modifiers in Hereditary and Wild-Type TTR Amyloidosis: Update on Genome-wide Association Study

Vegezzi, E, Quartesan, I, Facchini, S, Curro, R, Mussinelli, R, Palladini, G, Milani, P, Nuvolone, M, Anan, I, Todorova, A, Tournev, I, Hegenbart, U, Schönland, S, Siepen, F, Gillmore, JD, Razvi, Y, Rowczenio, D, Coelho, T, Lemos, C, Alves-Ferreira, M, Mandich, P, Conceicao, I, Marques, W Jr, Tomaselli, P, Alves, G, Planté-Bordeneuve, V, Perrain, V, Hahn, K, Reilly, MM, Houlden, H, Pons, CC, Morales, M, Fabrizi, GM, Tagliapietra, M, Knoll, K, Trenkwalder, T, Cappelli, F, Argirò, A, Arregui, ALD, Agudo, PI, Torrón, RF, Arana-Achaga, X, Goena-Vives, C, Martinez, MLP, Aguirre, MA, Saez, M, Cisneros-Barroso, E, Luigetti, M, Berk, J, Prokaeva, T, Sekijima, Y, Yoshinaga, T, Garcia, SK, Théaudin, M, Guaraldi, P, Gragera, A, Rojas-García, R, Carbayo-Viejo, A, Gonzalez-Duarte, A, Cardenas-Soto, K, Menao, S, Kleopa, K, Zamba-Papanicolaou, E, Christodoulou, C, Waddington-Cruz, M, Foguel, D, Russo, M, Mazzeo, A, Sevilla, T, Sivera, R, Tasaki, M, Ueda, M, Reisin, R, Cejas, LL, Petit, C, Di Stefano, V, Antonini, G, Leonardi, L, Sanchez-Tejerina, D, Manganelli, F, Tozza, S, Pareyson, D, Fenu, S, Briani, C, Salvalaggio, A, Obici, L, Cortese, A. Genetic Modifiers in Hereditary and Wild-Type TTR Amyloidosis: Update on Genome-wide Association Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

01/06/2025 Safety and efficacy data from the phase 2 ARDA study of empasiprubart in multifocal motor neuropathy

Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, van de Walle, I, Persson, E, Vujcic, M, van de Steen, O, Allen, J, Orazio, EN, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, W. Safety and efficacy data from the phase 2 ARDA study of empasiprubart in multifocal motor neuropathy. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Safety and efficacy of riliprubart in chronic inflammatory demyelinating polyneuropathy: 76-week phase 2 trial results

Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and efficacy of riliprubart in chronic inflammatory demyelinating polyneuropathy: 76-week phase 2 trial results. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Effect of efgartigimod PH20 SC on lower limb function in chronic inflammatory demyelinating polyneuropathy in ADHERE

Rinaldi, S, Allen, J, Lin, J, Stettner, M, Merkies, I, Guptill, J, Hewamadduma, C, Istas, G, De Roeck, A, Kuwabara, S, Lauria, G, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Echaniz-Laguna, A, Van Hoorick, B, Yamasaki, R, Lewis, R, van Doorn, P. Effect of efgartigimod PH20 SC on lower limb function in chronic inflammatory demyelinating polyneuropathy in ADHERE. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Proteomic profiling of Guillain-Barre Syndrome using aptamers: Identifying and Validating Potential Biomarkers

Collet-Vidiella, R, Aguilar, LM, Lleix , C, Caballero-Avila, M, Illa, CT, Go i, EP, Llarch, P, Lluci -Carol, L, Tous, MS, Casasnovas, C, Guti rrez-Guti rrez, G, Fern ndez, JP, Carbayo, A, Gallardo, E, Vesperinas, A, Llanso, L, Fern ndez-Cadenas, I, Querol, L. Proteomic profiling of Guillain-Barre Syndrome using aptamers: Identifying and Validating Potential Biomarkers. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Chat-GPT-4o in diagnosis and management of real-life polyneuropathy cases: Comparative analysis with neurologists

De Lorenzo, A, Moretti, G, Bertini, A, Collet-Vidiella, R, Fasolino, A, Fortanier, E, Hadden, R, Islam, B, Kleopa, K, Cejas, LL, Leonardi, L, Mira, V, Peric, S, Rajabally, Y, Sevilla, T, Tomaselli, P, Tozza, S, Pisciotta, C, Pareyson, D, Nobile-Orazio, E, Doneddu, P. Chat-GPT-4o in diagnosis and management of real-life polyneuropathy cases: Comparative analysis with neurologists. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Immune checkpoint inhibitor-related myositis-myasthenia: A retrospective cohort study in Spain

Hernandez, EM, Maqueda, JC, Fonseca, E, Marco, C, Chico, J, Fernandez, JG, Llaurado, A, Cabello, J, del Pino, L, Izquierdo, C, Cortes, E, G llego, J, Ros, M, Cald , R, Pelayo, A, Vizcaino, CS, Hernandez, H, Alvarez, J, Simo, M, Dalmau, J, Bruna, J, Velasco, R. Immune checkpoint inhibitor-related myositis-myasthenia: A retrospective cohort study in Spain. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Efficacy of Riliprubart in chronic inflammatory demyelinating polyneuropathy: Phase 2 subgroup analyses

Lewis, RA, Querol, L, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Lu, Y, Alonso, MA, Atassi, N, Hughes, AC. Efficacy of Riliprubart in chronic inflammatory demyelinating polyneuropathy: Phase 2 subgroup analyses. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Managing multifocal motor neuropathy: A survey of neurologists from Japan, Canada, and six European countries

Querol, L, Lewis, R, Sommer, C, Bromberg, M, Barrera-Sierra, S, Arvin-Berod, C, Nisbet, P, Gelinas, D, Guptill, J, Wood, J. Managing multifocal motor neuropathy: A survey of neurologists from Japan, Canada, and six European countries. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Psychometric evaluation of resistance to change questionnaire: reluctance to adopt new treatments in myasthenia gravis

Reyes, V, Maurino, J, Armangu , T, Querol, L, Guti rrez-Guti rrez, G, Sotoca, J, Ares, A, Villaverde, R, Salas, E, D az-Abos, P, Cort s-Vicente, E, Gomez-Ballesteros, R, Ballesteros, J. Psychometric evaluation of resistance to change questionnaire: reluctance to adopt new treatments in myasthenia gravis. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Quality of life in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG

Sacconi, S, Antozzi, C, Cortes-Vicente, E, Pascuzzi, R, Utsugisawa, K, Vissing, J, Vu, T, Bloemers, J, Grimson, F, Tarancon, T, Bril, V. Quality of life in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/06/2025 Efgartigimod in pretreated patients with CIDP and progressive/relapsing or persistent disease activity

Skripuletz, T, Allen, J, Rinaldi, S, Lauria, G, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Stettner, M, Lewis, R, van Doorn, P. Efgartigimod in pretreated patients with CIDP and progressive/relapsing or persistent disease activity. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).